At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
Afegostat tartratedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-label Study to Assess the Safety and Tolerability of Multiple Dose Levels and Multiple Dosing Regimens of AT2101 in Adult Patients With Type 1 Gaucher Disease Currently Receiving Enzyme Replacement Therapy
In Brief
A Phase 2 clinical trial evaluating Afegostat tartrate for Gaucher Disease, Type 1 and 2 related conditions. Completed, enrolled 30 participants across 10 sites.
Detailed Summary
This study was conducted to test the safety and tolerability of afegostat tartrate in participants with type 1 Gaucher disease already receiving enzyme replacement therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 2007
Enrollment StartMar 2007
Primary CompletionFeb 2008
TodayJul 2026
First PostedFeb 9, 2007
Enrollment StartMar 23, 2007
Primary CompletionFeb 19, 2008
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 19.4 years ago
Interventions
Afegostat tartratedrug